奠定基础:PARTIQoL试验中质子治疗对比调强放射治疗局限性前列腺癌的可行性与基线特征
PARTIQoL试验(NCT01617161)是一项多中心3期随机试验,比较质子束治疗(PBT)与光子调强放射治疗(IMRT)用于低危或中危局限性前列腺癌。2012年7月至2021年11月共入组450例患者,随机分配至PBT组(226例)或IMRT组(224例),437例纳入分析,中位年龄68岁(范围46-89岁),41%低危、59%中危。试验证明通过针对性招募、多中心协作、支付方参与和方案更新,开展大型3期随机试验是可行的。
要点
- PARTIQoL试验成功入组450例低危或中危局限性前列腺癌患者,随机分配至PBT组226例或IMRT组224例。
- 437例分析患者中位年龄68岁(范围46-89岁),41%低危、59%中危,49%常规分割、51%中度大分割。
- 48%患者使用直肠间隔物,PBT组中48%采用笔束扫描,两治疗组基线变量均衡。
核心结论
- 尽管面临重大挑战,PARTIQoL试验证明通过针对性招募、多中心协作、支付方参与和方案更新纳入当代技术,开展大型3期随机临床试验以评估PBT是否改善结局是可行的。
- 主要结果将另行报告,并将继续监测参与者以获取更长期随访和次要终点数据。
研究设计与样本
- 多中心3期随机试验(NCT01617161),比较质子束治疗(PBT)与光子调强放射治疗(IMRT)用于低危或中危局限性前列腺癌。
- 按机构、年龄、直肠间隔物使用和分割方案(常规分割:79.2 Gy分44次 vs 中度大分割:70.0 Gy分28次)进行分层随机。
- 主要终点为放疗后24个月采用扩展前列腺指数综合评分评估肠道健康相对基线的变化。
- 次要目标包括泌尿和勃起功能、不良事件及疗效终点的治疗相关差异。
主要发现
- 2012年7月至2021年11月共成功入组450例患者,随机分配至PBT组(N=226)或IMRT组(N=224);13例不合格或治疗前退出。
- 437例分析患者中位年龄68岁(范围46-89岁),41%为低危、59%为中危疾病。
- 49%患者接受常规分割,51%接受中度大分割;48%患者使用直肠间隔物。
- 接受PBT的患者中48%采用笔束扫描;PBT组和IMRT组基线变量均衡。
局限性
- 原文报告试验面临重大挑战(significant challenges)。
- 主要结果将另行报告,并将继续监测参与者以获取更长期随访和次要终点数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Men with localized prostate cancer may receive either photon-based intensity modulated radiation therapy (IMRT) or proton beam therapy (PBT). The PARTIQoL trial (NCT01617161) demonstrates the feasibility of performing a large, multicenter phase 3 randomized trial comparing IMRT with PBT for localized prostate cancer. Here, we report baseline features of patients enrolled on this trial and present strategies to improve feasibility of other similar trials. METHODS AND MATERIALS: Patients with low- or intermediate-risk prostate cancer were randomly assigned to either PBT or IMRT with stratification by institution, age, use of rectal spacer, and fractionation schedule (conventional fractionation: 79.2 Gy in 44 fractions vs moderate hypofractionation: 70.0 Gy in 28 fractions). The primary endpoint is a change from baseline bowel health using the Expanded Prostate Index Composite score 24 months after radiation therapy. Secondary objectives include treatment-related differences in urinary and erectile functions, adverse events, and efficacy endpoints. RESULTS: Between July 2012 and November 2021, 450 patients were successfully accrued. Patients were randomly assigned to either PBT (N = 226) or to IMRT (N = 224); 13 were ineligible or withdrew before treatment. The median age of 437 analyzed patients was 68 years (range, 46-89 years). A total of 41% of patients had low-risk and 59% had intermediate-risk disease. In total, 49% of patients were treated with conventional fractionation and 51% with moderately hypofractionation. 48% of patients used a rectal spacer. For patients receiving PBT, pencil beam scanning was used in 48%. PBT and IMRT arms were balanced for baseline variables. CONCLUSIONS: Despite significant challenges, the PARTIQoL trial demonstrated that, with targeted recruitment approaches, multicenter collaboration, payer engagement, and protocol updates to incorporate contemporary techniques, it is feasible to perform a large phase 3 randomized clinical trial to assess whether PBT improves outcomes. We will separately report primary results and continue to monitor participants for longer follow-up and secondary endpoints.
引用
- Wisdom AJ, Yeap BY, Michalski JM, et al. Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy Versus Intensity Modulated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 39357788. doi:10.1016/j.ijrobp.2024.09.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。